ClinicalTrials.gg
RecruitingNCT06716138Updated Mar 13, 2026

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of ANS03 in Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration, sponsored by Avistone Biotechnology Co., Ltd.. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Avistone Biotechnology Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS03 as monotherapy.

02

Conditions studied

  • Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration

Keywords

  • ROS1/NTRK
  • ANS03
  • ROS1
  • NTRK
03

In context

Lead sponsor

Avistone Biotechnology Co., Ltd. is the lead sponsor of 12 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • (ECOG) Performance Status: 0-2
  • ≥ 12 weeks
  • per v1.1
  • Adequate organ and marrow function as defined in the protocol
  • With documentation of ROS1 or NTRK alteration

Exclusion criteria

Exclusion Criteria:

  • Active infection including tuberculosis and , or
  • Known active or untreated
  • Participants with carcinomatous meningitis or meningeal , or spinal cord compression
  • Participants with serious cardiovascular or cerebrovascular diseases
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    ANS03 monotherapy

    Drug: ANS03

Interventions

  • DrugANS03

    ANS03 is a rationally next generation TKI targeting both ROS1 and NTRK developed by Shenzhen Avistone Biotechnology (the sponsor).

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Number of patients with adverse events by system organ class and preferred term

    Time frame: From the time of first dose to 28 days post last dose of ANS03

  2. Incidence of Serious Adverse Events (SAEs)

    Number of patients with serious adverse events by system organ class and preferred term

    Time frame: From time of first dose to 28 days post last dose of ANS03

  3. Incidence of dose-limiting toxicities (DLT) as defined in the protocol

    Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol

    Time frame: From time of first dose of ANS03 to end of DLT period (approximately 30 days)

  4. Incidence of baseline laboratory finding, ECG and vital signs changes

    measured by laboratory and vital sign variables over time including change from baseline

    Time frame: From time of first dose to 28 days post last dose of ANS03

  5. Proportion of patients with radiological response (ORR)

    Assessed by overall response rate (ORR) defined as the proportion of patients who have a confirmed complete or partial radiological response by the Investigator according to RECIST v1.1

    Time frame: From date of first dose of ANS03 until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)

Secondary outcomes

  1. Objective Response Rate (ORR)

    The percentage or number of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST v1.1)

    Time frame: From date of first dose of ANS03 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)

  2. Duration of Response (DoR)

    The time from date of first response until date of disease progression or last evaluable assessment (RECIST v1.1) in the absence of progression

    Time frame: From date of first dose of ANS03 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)

  3. Disease Control Rate (DCR)

    The percentage of patients with confirmed CR or PR or having SD maintained (RECIST v1.1)

    Time frame: From date of first dose of ANS03 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years)

  4. Progression free Survival (PFS)

    The time from first dose until RECIST 1.1 defined disease progression or death due to any cause

    Time frame: From date of first dose of ANS03 up until date of progression or death due to any cause (approximately 2 years)]

  5. Overall Survival (OS)

    The time from the date of the first dose of study treatment until death due to any cause

    Time frame: From date of first dose of ANS03 up until the date of death due to any cause (approximately 2 years)

  6. Pharmacokinetics of ANS03: Plasma PK concentrations

    Measurement of plasma concentrations of ANS03, total antibody and total unconjugated warhead

    Time frame: From date of first dose up until 28 days post last dose

  7. Pharmacokinetics of ANS03: Area under the concentration time curve (AUC)

    Measurement of PK parameters: Area under the concentration time curve (AUC)

    Time frame: From date of first dose up until 28 days post last dose

  8. Pharmacokinetics of ANS03: Maximum plasma concentration of the study drug (C-max)

    Measurement of PK parameters: Maximum observed plasma concentration of the study drug (C-max)

    Time frame: From date of first dose up until 28 days post last dose

  9. Pharmacokinetics of ANS03: Time to maximum plasma concentration of the study drug (T-max)

    Measurement of PK parameters: Time to maximum observed plasma concentration of the study drug (T-max)

    Time frame: Frame: From date of first dose up until 28 days post last dose

  10. Pharmacokinetics of ANS03: Clearance

    Measurement of PK parameters: the volume of plasma from which the study drug is completely removed per unit time (Clearance)

    Time frame: From date of first dose up until 28 days post last dose

  11. Pharmacokinetics of ANS03: Half-life

    Measurement of PK parameters: Terminal elimination half-life (t 1/2)

    Time frame: From date of first dose up until 28 days post last dose

07

Study locations

5 of 5 sites recruiting
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10022, United States
    Recruiting
  • Research Site
    Fuzhou, Fujian, China
    Recruiting
  • Research Site
    Guangzhou, Guangdong, China
    Recruiting
  • Research Site
    Shanghai, Shanghai Municipality, China
    Recruiting
  • Research Site
    Chengdu, Sichuan, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Dec 2027, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2024
First posted
Dec 4, 2024
StartActual
Mar 6, 2025
Primary completionEst.
Dec 30, 2027
CompletionEst.
Mar 30, 2029
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06716138
Lead sponsor
Avistone Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Dec 4, 2024
Start date
Mar 6, 2025
Primary completion
Dec 30, 2027 (estimated)
Completion
Mar 30, 2029 (estimated)
Last update
Mar 13, 2026

Study contacts

Avistone Clinical Study Information Center
Contact
information.center@avistonebio.com
8610 84148921

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion